Aquinox Pharmaceuticals, Inc
Aquinox Pharmaceuticals, Inc. (Aquinox, NASDAQ:AQXP) is a clinical-stage pharmaceutical company developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers. We are dedicated to advancing novel therapeutics that we believe will make a clinically meaningful difference in patients’ lives. Aquinox’s lead drug candidate rosiptor (AQX-1125) is a first-in-class, once-daily, oral treatment being studied for its effects on inflammation and inflammatory pain. Rosiptor is currently being evaluated in a randomized, double-blind, placebo-controlled, Phase 3 clinical trial (LEADERSHIP 301) to assess its effect on bladder pain and urinary symptoms in female and male subjects with interstitial cystitis/bladder pain syndrome (IC/BPS), with topline data anticipated in Q3 2018.
Conference Objective
To participate in the partnering forum
Partnering Objective
Meeting with potential partners that would like to collaborate on the early and late stage programs directed towards immuno-oncology and anti-inflammatory diseases.
Delegate Contacts
Mr. Brennan brings more than 25 years of experience in building and leading pharmaceutical and biotechnology companies internationally and has a strong track record in regulatory affairs, market development, and partnering. Within biotech Mr. Brennan has held executive positions at several companies including Arbutus Biopharma, Aspreva and AnorMED. Mr. Brennan played a significant role in the sale of Aspreva to Vifor Pharma for $915 million, the sale of AnorMED to Genzyme for $580 million, and the merger of Tekmira and OnCore to create Arbutus Biopharma. Mr. Brennan also served in senior business development and regulatory affairs roles with AstraZeneca in Sweden, the UK and Canada.